· Published by Health Canada · Official notice
This is duplicated text of a letter from Hospira Healthcare Corporation. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
Novembre 27, 2013
Dear Chief of Medical Staff and Director of Pharmacy
Please distribute to relevant Departments (Oncology, Pharmacy, Geriatrics, Internal Medicine, Nursing, Paediatrics, Intensive Care Unit, Coronary Care, Emergency Department, Surgery, Recovery Room, Anaesthesiology and/or other Departments as required), and other involved professional staff and post this Notice in the relevant areas of your institution.
Subject: Recall of one lot of Marcaine (bupivacaine hydrochloride injection USP) 0.25% (50mg/20mL), lot # 28095DD, product # 02073020 (DIN 02241918) due to presence of an embedded particle on the glass vial
Hospira Healthcare Corporation, in consultation with Health Canada, would like to inform you of a recall of one lot of Marcaine (bupivacaine hydrochloride injection USP) 0.25% (50mg/20mL) as a result of a complaint received by Hospira due to the presence of an embedded iron particle on the inside wall of one vial.
“Marcaine is indicated for the production of local or regional anaesthesia and analgesia with the following procedures: local infiltration procedures, peripheral nerve blocks, retrobulbar blocks and caudal, epidural and subarachnoid (spinal) blocks.” (Canadian Product Monograph, Marcaine (bupivacaine hydrochloride injection USP) 0.25%, April 6, 2011; page 4.)
This lot of Marcaine was distributed between September 2013 and November 2013. Hospira’s investigation is on-going to determine the root cause and corrective and preventive actions.
Hospira has not received any reports of adverse events associated with this lot of Marcaine (bupivacaine hydrochloride injection USP) 0.25% (50mg/20mL) from its customers.
| Product | DIN | List Number | Lot Number | Expiry Date |
| Marcaine (bupivacaine hydrochloride injection USP) 0.25% 50mg/20mL | 02241918 | 02073020 | 28095DD | April 1, 2015 |
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious adverse reaction or other serious or unexpected adverse reactions in patients receiving Marcaine (bupivacaine hydrochloride injection) should be reported to Hospira Healthcare Corporation or Health Canada at the following addresses:
Hospira Healthcare Corporation
1111 Dr.-Frederik-Philips, Suite 600
Saint-Laurent (Québec) H4M 2X6
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 1-866-488-6088 Option 6
Fax: 1-877-906-0208
ProductcomplaintsCA@hospira.com
To correct your mailing address or fax number, contact: Hospira Healthcare Corporation.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other heath product inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-946-5636
Sincerely,
Original signed by
Rania Al-Ammar
Regional Director, Commercial Quality
Hospira Healthcare Corporation